Johnson & Johnson

NYSE:JNJUnited States

Oct 28, 2024

Show headlines and story abstract

• DJ AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update, from 11:52AM ET on Monday Oct 28, 2024 by Dow Jones

  11:52AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: JNJ, ABBV
  
  By Colin Kellaher
  
  AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash in a deal that adds a potential therapy for Alzheimer's disease to AbbVie's neuroscience pipeline.
  

• DJ What the Election Will Mean for CVS, Pfizer, and Other Healthcare Stocks -- Barrons.com, from 9:28AM ET on Monday Oct 28, 2024 by Dow Jones

  9:28AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: HUM, JNJ, PFE, UNH, CVS
  
  By Josh Nathan-Kazis
  
  Healthcare played only a modest role in the 2024 presidential race, but the outcome could have major impacts on health insurers and hospital companies.
  

• Johnson & Johnson Says Phase 3 Trial of Crohn's Disease Treatment Showed High Remission Rates, from 8:19AM ET on Monday Oct 28, 2024 by MT Newswires

  8:19AM ET on Monday Oct 28, 2024 by MT Newswires
  Companies Mentioned: JNJ
  08:19 AM EDT, 10/28/2024 (MT Newswires) -- Johnson & Johnson (JNJ) said Monday that results from a phase 3 study of Tremfya as a treatment for Crohn's disease showed high remission rates among tested patients. The first 12 weeks of the trial where T...

• TREMFYA(R) (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease, from 7:30AM ET on Monday Oct 28, 2024 by Dow Jones

  7:30AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: JNJ
  
  TREMFYA(R) is a prescription medicine that may cause serious side effects, including:
  -- Serious Allergic Reactions. Stop using TREMFYA(R) and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: -- fainting, dizziness, feeling lightheaded (low blood pressure) -- swelling of your face, eyelids, lips, mouth, tongue, or throat -- trouble breathing or throat tightness -- chest tightness -- skin rash, hives -- itching -- Infections. TREMFYA(R) may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA(R) and may treat you for TB before you begin treatment with TREMFYA(R) if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA(R).